Evidence map›Paper›PMID 26927866›Full record

ArticleJournal of medicinal chemistry2016

3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations.

Jing Tang, Feng Liu, Eva Nagy, Lena Miller, Karen A Kirby, Daniel J Wilson, Bulan Wu, Stefan G Sarafianos, Michael A Parniak, Zhengqiang Wang

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jing TangCenter for Drug Design, Academic Health Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Feng LiuCenter for Drug Design, Academic Health Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Eva NagyDepartment of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania 15219, United States.
Lena MillerDepartment of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania 15219, United States.
Karen A KirbyDepartment of Molecular Microbiology and Immunology and Department of Biochemistry, University of Missouri School of Medicine , Christopher S. Bond Life Sciences Center, Columbia, Missouri 65211, United States.
Daniel J WilsonCenter for Drug Design, Academic Health Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Bulan WuCenter for Drug Design, Academic Health Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Stefan G SarafianosDepartment of Molecular Microbiology and Immunology and Department of Biochemistry, University of Missouri School of Medicine , Christopher S. Bond Life Sciences Center, Columbia, Missouri 65211, United States.
Michael A ParniakDepartment of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania 15219, United States.
Zhengqiang WangCenter for Drug Design, Academic Health Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
University of Minnesota · USUniversity of Pittsburgh · USUniversity of Missouri · US

Funding

Novel antivirals targeting the RNase H activity of HIV reverse transcriptaseR01AI100890 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G, WANG, ZHENGQIANG · 2012 to 2016
$3.6M
NIAID NIH HHS AI100890NIAID NIH HHS R01 AI100890
6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains an unvalidated antiviral target. A major challenge of specifically targeting HIV RNase H arises from the general lack of selectivity over RT polymerase (pol) and integrase (IN) strand transfer (ST) inhibitions. We report herein the synthesis and biochemical evaluations of three novel 3-hydroxypyrimidine-2,4-dione (HPD) subtypes carefully designed to achieve selective RNase H inhibition. Biochemical studies showed the two subtypes with an N-1 methyl group (9 and 10) inhibited RNase H in low micromolar range without significantly inhibiting RT polymerase, whereas the N-1 unsubstituted subtype 11 inhibited RNase H in submicromolar range and RT polymerase in low micromolar range. Subtype 11 also exhibited substantially reduced inhibition in the HIV-1 INST assay and no significant cytotoxicity in the cell viability assay, suggesting that it may be amenable to further structure-activity relationship (SAR) for identifying RNase H inhibitors with antiviral activity.

Indexed as

Anti-HIV AgentsCatalytic DomainDNA-Directed RNA PolymerasesDrug DesignHIV-1HIV Reverse TranscriptaseHumansModels, MolecularPolymerase Chain ReactionReverse Transcriptase InhibitorsRibonuclease H, Human Immunodeficiency VirusStructure-Activity RelationshipUracilAnti-HIV AgentsDNA-Directed RNA PolymerasesHIV Reverse TranscriptaseReverse Transcriptase InhibitorsRibonuclease H, Human Immunodeficiency VirusUracil

Identifiers

PMID26927866
PMCPMC4871627
OpenAlexW2299248937

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.